Biden's Latest Shortage Is Kids' Medicine

Vaccines, baby formula, groceries, you name it, Joe Biden's administration has had a shortage of it.

This time, there's a children's medicine shortage.

Business Insider broke the news to America that Biden is facing another shortage, and there isn't any end in sight for this one either, noting:

A shortage of children’s medications is leaving parents scrambling to care for their kids as three potentially deadly diseases permeate the United States. The explosion of the three illnesses has left parents demanding more medications than stores and suppliers anticipated — leading to a shortage.

Everybody is sick, and everybody needs medicine at once, and companies can’t keep up with the high demand, Joanna Dolgoff, a pediatrician and spokeswoman for the American Academy of Pediatricians, told the Washington Post this month.

And with short supply, retailers from CVS to Walgreens to Target have limited the amount of children’s pain medication customers can purchase at once.

This follows last month's amoxicillin shortage, as well as the recent continued drought of baby formula, with the outlet adding:

Among the challenges is a scarcity in amoxicillin, which the Centers of Disease Control and Prevention considers a 'first-line therapy' for bacterial ear infections and other common illnesses in children. The U.S. Food and Drug Administration added amoxicillin oral powder for suspension to its list of drug shortages in late October, stoking concerns among parents, pharmacists and physicians.

These shortages have been associated with the uptick in influenza and respiratory syncytial virus (RSV) infections, as well as COVID-19 infections. This has resulted in the hoarding of liquid acetaminophen and ibuprofen, used to treat fever and pain, from several pharmacies, by consumers. The shortage of these products is common in the U.S. Antibiotic usage has increased 46% around the world since 2000, and amoxicillin is a medication that is in high demand globally. Only a few countries produce the active pharmaceutical ingredient for amoxicillin, and some of these manufacturers have also suffered regulatory sanctions and are unable to continue to manufacture and supply these products.